+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence of dyslipidemia and borderline dyslipidemia in aging residents from Beijing communities



Prevalence of dyslipidemia and borderline dyslipidemia in aging residents from Beijing communities



Zhonghua Yi Xue Za Zhi 93(46): 3675-3679



To investigate the prevalence characters of dyslipidemia and borderline dyslipidemia in aging residents from Beijing communities and to evaluate the relative risk of cardiovascular risk factor (CRF) to dyslipidemia. The samples were selected by random cluster multistage method. Serum lipid level and CRF were determined through questionnaire, physical examination and biochemical detection for 1974 subjects who was 65 and over 65 years old in Beijing communities. Age- and sex-adjusted standardized incidence of dyslipidemia and borderline dyslipidemia in ≥ 65 yrs was 35.11% (693/1974) and 28.57% (564/1974) respectively, optimal lipid was 36.32% (717/1974).Vs optimal status 3 borderline factors(BF) , 1 major CRF, 2 CRFs, and 3 CRFs to have dyslipidemia, the relative risks are OR = 1.537, 95%CI 0.597-3.959, OR = 1.898, 95%CI 0.993-3.628, OR = 2.441, 95%CI 1.268-4.698, and OR = 4.256, 95%CI 2.104-8.608 respectively. The prevalence of major CRFs of ≥ 65 yrs resident from Beijing communities are higher than the average level of China. The risk is higher while the number of borderline and major CRFs much more.

(PDF emailed within 1 workday: $29.90)

Accession: 055157397

Download citation: RISBibTeXText

PMID: 24534348


Related references

Prevalence of dyslipidemia and borderline dyslipidemia and other risk factors of coronary heart disease in residents from Beijing communities. Zhonghua Xin Xue Guan Bing Za Zhi 38(2): 175-180, 2011

Factors associated with dyslipidemia awareness among residents in Beijing results from CCEIP. Zhongguo Shiyong Neike Zazhi: 1, 38-40, 2010

Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Canadian Journal of Cardiology 26(9): E330-E335, 2011

Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. Journal of Pediatric Endocrinology and Metabolism 2019, 2019

Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS). Medicina 50(1): 44-53, 2016

Prevalence, awareness, treatment, and control of dyslipidemia among adults in Beijing, China. Journal of Atherosclerosis and Thrombosis 19(2): 159-168, 2012

Prevalence and awareness of dyslipidemia among overweight and obese population in Beijing community. Zhonghua Xin Xue Guan Bing Za Zhi 38(6): 562-566, 2011

Prevalence rate of metabolic syndrome and dyslipidemia in a large professional population in Beijing. Atherosclerosis 184(1): 188-192, 2005

Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing. Clinical Chemistry 51(1): 144-150, 2004

Study on the prevalence of dyslipidemia and associated dietary risk factors among adults in Shunyi District of Beijing. Wei Sheng Yan Jiu 42(4): 565-570, 2014

Prevalence of dyslipidemia among residents aged 18-69 years in Shandong province of China, 2011. Zhonghua Yu Fang Yi Xue Za Zhi 50(3): 230-234, 2016

Prevalence of overweight/obesity and its associations with hypertension, diabetes, dyslipidemia, and metabolic syndrome: a survey in the suburban area of Beijing, 2007. Obesity Facts 4(4): 284-289, 2012

Prevalence of dyslipidemia and general ineffectiveness of its treatment in both primary and secondary prevention of coronary heart disease within family medicine framework--results of LIPIDOGRAM 2005--a nationwide epidemiological study. Dyslipidemia in Poland--ineffective treatment. Przeglad Lekarski 65(12): 834-837, 2009

Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease. Vascular and Endovascular Surgery 50(2): 119-135, 2016

The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia. Annals of Translational Medicine 5(23): 477, 2017